Please login to the form below

Not currently logged in

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Resistance is futile?

Debating the inevitability of transparency

The ethics and practicality of data collection and sharing, whether in clinical trials, doctors' performance or a country's defence programme, is a common issue in these connected times.

What should be shared publicly, and with whom, is often contentious, and pharma is by no means alone when it comes to feeling the pressure to open archives and release data.

There certainly seems no escape from trial transparency. For Bad Pharma author Dr Ben Goldacre the industry is following an “inevitable policy trajectory”, he told PME that after the recent European Parliament Committee vote on amending the Clinical Trial Directive the direction of travel “cannot be held back”.

A slightly more nuanced approach can be found in PME magazine, where UCB's Neir Weir says the debate is driven, on both sides, by people who passionately want to do the right thing.

Certainly, we are all aware of the reasons why there is a need for transparency, but it's also becoming clearer and clearer that the issue is a delicate and complex one.

This blog post first appeared as the Editor's comment in PME July/August 2013

Article by
David Stone

is editor of PME and Communiqué

8th August 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?